tetano
Editor, Senior Moderator
Immunotherapy. 2016 Jul 5. [Epub ahead of print]
[h=1]Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.[/h] Herbreteau CH[SUP]1[/SUP], Denizot M[SUP]1[/SUP], Lowther S[SUP]2[/SUP], Riddell S[SUP]2[/SUP], Frazer L[SUP]2[/SUP], Haining J[SUP]2[/SUP], Arkinstall R[SUP]2[/SUP], Payne J[SUP]2[/SUP], Harper J[SUP]2[/SUP], Johnson D[SUP]2[/SUP], Pasquier A[SUP]1[/SUP], Middleton D[SUP]2[/SUP], Saluzzo JF[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIM:[/h] Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1.
[h=4]METHODS:[/h] Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy.
[h=4]RESULTS:[/h] Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival.
[h=4]CONCLUSION:[/h] FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.
[h=4]KEYWORDS:[/h] A/H5N1; F(ab')2; avian influenza; ferret; immunoglobulin; oseltamivir
PMID: 27380317 DOI: 10.2217/imt-2016-0062
[PubMed - as supplied by publisher]
[h=1]Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.[/h] Herbreteau CH[SUP]1[/SUP], Denizot M[SUP]1[/SUP], Lowther S[SUP]2[/SUP], Riddell S[SUP]2[/SUP], Frazer L[SUP]2[/SUP], Haining J[SUP]2[/SUP], Arkinstall R[SUP]2[/SUP], Payne J[SUP]2[/SUP], Harper J[SUP]2[/SUP], Johnson D[SUP]2[/SUP], Pasquier A[SUP]1[/SUP], Middleton D[SUP]2[/SUP], Saluzzo JF[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIM:[/h] Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1.
[h=4]METHODS:[/h] Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy.
[h=4]RESULTS:[/h] Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival.
[h=4]CONCLUSION:[/h] FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.
[h=4]KEYWORDS:[/h] A/H5N1; F(ab')2; avian influenza; ferret; immunoglobulin; oseltamivir
PMID: 27380317 DOI: 10.2217/imt-2016-0062
[PubMed - as supplied by publisher]